Structure Therapeutics Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Structure Therapeutics Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($141.20M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($122.53M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($89.62M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($51.32M) | Mar 8, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($176.56M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($158.23M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($102.78M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($52.56M) | Mar 8, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $225.26M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $108.81M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $70.10M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $36.19M | Mar 8, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($222.20M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($116.64M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($79.49M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($46.12M) | Mar 8, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.61M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.29M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.17M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $155.0K | Mar 8, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.58B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $903.33M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $482.02M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $97.85M | Mar 8, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.54M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $38.49M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $29.05M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $13.01M | Mar 8, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.52B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $864.84M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $452.97M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | ($115.14M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2021 | ($64.74M) | Mar 8, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($470.30M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($329.10M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($206.57M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($116.95M) | Mar 8, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $799.62M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $169.51M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $129.79M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $26.09M | Mar 8, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | (5) | Mar 8, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | (5) | Mar 8, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 212.51M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 171.86M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 139.22M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 10.53M | Mar 8, 2024 |